CHF 6001

Drug Profile

CHF 6001

Alternative Names: CHF 6001 NEXThaler; CHF 6001 NEXThaler DPI; CHF-6001

Latest Information Update: 15 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chiesi Farmaceutici
  • Class Antiasthmatics
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Allergic asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease(In volunteers) in Belgium (Inhalation, Powder)
  • 13 Sep 2017 Preclinical data in Asthma presented at the 27th Annual Congress of the European Respiratory Society (ERS-2017)
  • 13 Dec 2016 Phase-II clinical trials in Chronic obstructive pulmonary disease (Adjunctive treatment) in Poland (Inhalation) (EudraCT2015-005548-32)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top